Succinate based polymers drive immunometabolism in dendritic cells to generate cancer immunotherapy

J Control Release. 2023 Jun:358:541-554. doi: 10.1016/j.jconrel.2023.05.014. Epub 2023 May 15.

Abstract

Boosting the metabolism of immune cells while restricting cancer cell metabolism is challenging. Herein, we report that using biomaterials for the controlled delivery of succinate metabolite to phagocytic immune cells activates them and modulates their metabolism in the presence of metabolic inhibitors. In young immunocompetent mice, polymeric microparticles, with succinate incorporated in the backbone, induced strong pro-inflammatory anti-melanoma responses. Administration of poly(ethylene succinate) (PES MP)-based vaccines and glutaminase inhibitor to young immunocompetent mice with aggressive and large, established B16F10 melanoma tumors increased their survival three-fold, a result of increased cytotoxic T cells expressing RORγT (Tc17). Mechanistically, PES MPs directly modulate glutamine and glutamate metabolism, upregulate succinate receptor SUCNR1, activate antigen presenting cells through and HIF-1alpha, TNFa and TSLP-signaling pathways, and are dependent on alpha-ketoglutarate dehydrogenase for their activity, which demonstrates correlation of succinate delivery and these pathways. Overall, our findings suggest that immunometabolism-modifying PES MP strategies provide an approach for developing robust cancer immunotherapies.

Keywords: Cancer; Dendritic cells; Immune system; Metabolism; Succinate; Vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer Vaccines*
  • Dendritic Cells
  • Immunotherapy
  • Melanoma*
  • Mice
  • Polymers
  • Signal Transduction
  • Succinic Acid / metabolism

Substances

  • Polymers
  • Succinic Acid
  • Cancer Vaccines